行情

SBBP

SBBP

Strongbridge
NASDAQ

实时行情|Nasdaq Last Sale

1.810
+0.040
+2.26%
盘后: 1.810 0 0.00% 16:00 12/06 EST
开盘
1.790
昨收
1.770
最高
1.820
最低
1.740
成交量
14.70万
成交额
--
52周最高
5.69
52周最低
1.430
市值
9,811.26万
市盈率(TTM)
1.919
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SBBP 新闻

  • Strongbridge Biopharma (SBBP) Investor Presentation - Slideshow
  • Seeking Alpha - Article.2天前
  • 意大利最大商业银行拟裁员8000人
  • 新浪财经.3天前
  • 意大利总理支持欧洲稳定机制改革 遭反对党批评
  • 中国新闻网.3天前
  • 韩2019网购销售额破100万亿韩元 披萨炸鸡交易额剧增
  • 中国新闻网.3天前

更多

所属板块

制药
+0.53%
制药与医学研究
+0.68%

热门股票

名称
价格
涨跌幅

SBBP 简况

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
展开

Webull提供Strongbridge Biopharma plc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。